Anti-Human PD-L1 (Atezolizumab)

Anti-Human PD-L1 (Atezolizumab)

Product No.: LT1750

- -
- -
Product No.LT1750
Clone
RG7446
Target
PD-L1
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
Programmed Death Ligand 1, B7-H1, PD-L1, CD274
Isotype
Human IgG
Applications
FC
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Expression Host
HEK-293 Cells
FC Effector Activity
Active
Immunogen
Unknown
Product Concentration
0.5 mg/ml
Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Shipping
2-8°C Wet Ice
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for Atezolizumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Additional Applications Reported In Literature ?
WB
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Atezolizumab (RG7446; INN or code name MPDL3280A) activity is directed against PD-L1 (CD274) and B7.1 (CD80).
Antigen Distribution
PD-L1 is commonly expressed on the surface of antigen presenting cells (APC) and tumor cells. B7.1 is found on activated APCs including dendritic cells, macrophages, and activated B cells.
Background
Atezolizumab is a humanized, monoclonal immunoglobulin-G1 antibody that binds to programmed death ligand 1 (PD-L1; CD274) and B7.1 (CD80)1. PD-L1 is a transmembrane protein, widely expressed in many types of tissues, that acts as a ligand for the immune inhibitory receptor protein programmed death 1 (PD-1)2,3,4. Interaction between PD-1 and PD-L1 triggers inhibitory signals that dampen T cell function. PD-1 is expressed on activated T cells and is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. B7.1 is a transmembrane glycoprotein present on dendritic cells, activated B cells, and macrophages that induces T cell proliferation and cytokine production. When atezolizumab prevents binding of PD-L1 to B7.1, the T-cell-mediated immune response is further enhanced4.

Atezolizumab was isolated by screening a human phage display library against a recombinant extracellular domain-Fc fusion of human PD-L11,5. A high-affinity antibody was selected from a single phage clone on a human IgG1 backbone. Because PD-L1 is expressed on activated T cells, the Fc region of atezolizumab was engineered to eliminate antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC)1. An Asn to Ala change at position 298 was introduced in the CH2 domain of each heavy chain, rendering atezolizumab effectorless and incapable of binding to human Fcγ receptors1,5. Atezolizumab does not interfere with the interaction of PD-1 with ligand PD-L2 (CD273).

Atezolizumab is used in cancer immunotherapy and has been approved for some patients by the FDA to treat hepatocellular carcinoma, melanoma, non-small cell lung cancer, small cell lung cancer, urothelial cancer, and triple negative breast cancer6.

Antigen Details

Ligand/Receptor
PD-1 (PDCD1)
Research Area
Cancer
.
Costimulatory Molecules
.
Immunology

References & Citations

1. Herbst RS, Soria JC, Kowanetz M, et al. Nature. 515(7528):563-567. 2014.
2. Freeman GJ, Long AJ, Iwai Y, et al. J Exp Med. 2000192(7):1027-1034. 2000.
3. Tsai KK, Zarzoso I, Daud AI. Hum Vaccin Immunother. 10(11):3111-3116. 2014.
4. NCI Dictionaries. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/atezolizumab
5. Irving H, Chiu H, et al, inventors; F Hoffmann La Roche AG, assignee. Anti-PD-L1 antibodies, compositions and articles of manufacture. US Patent US 8,217,149B2. July 10, 2012.
6. A to Z List of Cancer Drugs. https://www.cancer.gov/about-cancer/treatment/drugs/atezolizumab
Flow Cytometry
General Western Blot Protocol
Products are for research use only. Not for use in diagnostic or therapeutic procedures.